Clinical Trials Browser

Phase 3 × INDUSTRY × Nasopharyngeal Carcinoma × Clear all

NCT06976190 2026-01-20

Magic-C002

Phase 3 Recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT06118333 2025-09-30

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT05294172 2025-05-30

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

296 enrolled 1 FDA

Nasopharyngeal Carcinoma

NCT06629597 2025-02-10

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT02578641 2023-06-28

VANCE

Phase 3 Completed

330 enrolled 18 charts

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Nose Neoplasms, Epstein-Barr Virus Infections

NCT03601975 2019-02-04

Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma

Phase 3 Unknown

Nasopharyngeal Carcinoma